🌐Machine-translated with AI — the facts come from the issuing authority’s own notice (linked on this page); this language version was translated automatically by an AI model and is not reviewed. The original-language notice is authoritative. How we use AI →
🔴 Serious hazard — Reported risk: Výrobek obsahuje psychoaktivní kanabinoid (MDMB-PINACA), což je vysoce potenciální psychoaktivní látka působící na centrální nervový systém, a může proto způsobit duševní a behaviorální poruchy. Užívání této látky je spojeno s rizikem závažných toxických účinků, včetně akutní intoxikace, poruchy vědomí, duševních a behaviorálních poruch, neurologických komplikací a kardiovaskulárních účinků. Výrobek není v souladu s nařízením o obecné bezpečnosti výrobků.
Action taken by the authority
Type of economic operator to whom the measure were ordered
Retailer
Category of measure
Withdrawal of the product from the market
Date of entry into force
21/05/2026
Machine translation. This page was translated automatically from the English record we hold of the issuing authority’s notice. The English original is shown below and the authority’s own notice is linked above — both take precedence over this translation.
Product Name (original English): MEGA STRONG CANNA MIX SATIVA
Risk Description (original English): The product contains a psychoactive cannabinoid (MDMB-PINACA), which is a highly potential psychoactive substance acting on the central nervous system and can therefore cause mental and behavioural disorders. The use of this substance is associated with the risk of serious toxic effects, including acute intoxication, impaired consciousness, mental and behavioral disorders, neurological complications and cardiovascular effects.
Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.
ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.